Clinically significant patent ductus arteriosus (PDA) has been associated with significant morbidity in extremely low birth weight (ELBW) infants. Current management of ELBW infants with hemodynamically significant PDA includes supportive treatment, pharmacological therapy, and surgical ligation. All of these therapeutic options have their advantages and limitations. More recently, transcatheter PDA closure has been described as a viable option in this population. In this paper, we provide a comprehensive review of this emerging procedure.
| INTRODUC TI ON
The ductus arteriosus is an essential fetal structure that closes spontaneously within the first week of life in the vast majority of healthy infants. However, the incidence of patent ductus arteriosus (PDA) reported by the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network in preterm infants ranges from 20%-60% with an inverse relationship to birth weight. 1 In extremely low birth weight (ELBW) infants born prior to 24 weeks, the likelihood of spontaneous closure is less than 15%. 2 Nearly half of infants born less than 1000 g develop a hemodynamically significant PDA. 3 While there are structural differences in the PDA anatomy as classified by Krichenko, the predominant morphology in premature infants is the Fetal-type (F-type) PDA described as elongated and tubular with minimal tapering and tortuosity at the pulmonary end. 4, 5 Failure of ductal closure leads to a left to right shunt which can result in pulmonary overcirculation and left heart volume overload. 6 Additionally, delayed closure of the ductus arteriosus in ELBW infants has been associated with bronchopulmonary dysplasia, necrotizing enterocolitis, pulmonary hypertension, intraventricular hemorrhage, sepsis and infective endocarditis. The mortality risk in infants born before 29 weeks gestation increases 8-fold if PDA is present. 7 Clinically or hemodynamically significant PDAs are currently treated with a combination of supportive approaches, pharmacotherapy, or surgical ligation. Indomethacin and ibuprofen, both nonselective cyclooxygenase (COX) inhibitors, have an estimated PDA closure rate of 50%-65% in ELBW infants. Given their vasoconstrictive properties, these medications have been associated with renal insufficiency and intestinal perforation. 8, 9 Paracetamol (acetaminophen) is a new alternative to nonselective COX inhibitor pharmacotherapy with similar PDA closure rates and fewer reported side effects. 10, 11 While there is little consensus regarding subsequent management, patients with clinically significant PDA who fail pharmacological therapy are currently treated with expectant management, including positive pressure ventilation, fluid restriction and diuresis, or ultimately referred for surgical ligation. 12 Despite advancements in surgical technique, surgical ductal ligation in ELBW infants has largely fallen out of favor due to a paucity of proven survival benefits and associated early and long-term morbidity. 13, 14 Transcatheter PDA closure was pioneered in 1967 by Porstmann et al. 15 The initial transcatheter PDA closure techniques utilized large arterial and venous delivery sheaths which limited its use in the pediatric population. Today, transcatheter PDA closure is the procedure of choice in adults, children, and larger infants. 16 However, this modality has not been routinely used in ELBW infants due to concerns regarding overall medical fragility, fear of increased incidence of procedure-related adverse events, technical challenges involved in catheterizing extremely small patients and the absence of a suit- The earliest case of PDA occlusion successfully performed in a low-birth weight infant was reported in 2001. 19 The procedure involved using a right saphenous vein cut down and antegrade PDA coil occlusion approach in an 1180 g infant. Small case series of PDA closure in preterm infants with a median procedure weight of 1100 g (range 930-1800 g) and 2200 g (range 1600-2600 g) were subsequently reported in 2007 and 2010. 20, 21 Collectively, they showed that PDA coil occlusion using a transvenous femoral approach under fluoroscopy guidance in the catheterization suite was technically feasible and safe in a select cohort of preterm low birth weight infants. However, as noted by the authors, due to the relatively large size of the PDA in this population, the use of coils was limited to only about 10% of the population in need.
In 2011, Bentham et al. reported a novel echocardiographic guided technique to achieve percutaneous duct closure carried out in the NICU for three preterm infants with weights ranging from 1400 to 2185 g. 22 Femoral arterial access was used to place either coils or an Amplatzer ductal occluder (ADO II; Abbott Medical, Sylmar, California) device across the PDA. In an important breakthrough, transthoracic echocardiographic imaging was utilized instead of fluoroscopy to guide the procedure and evaluate device placement, residual shunt and surrounding arteries. This allowed for the procedure to be performed at the bedside, thereby avoiding significant risks associated with transportation of critically ill infants.
Additionally, it allowed for multiple treatment teams to coordinate care in one location and eliminated procedure-related contrast and radiation exposure risks. Unfortunately, this approach, which utilizes femoral arterial access without fluoroscopy, placed these infants at risk for limb ischemia and has limited management options for complications such as device embolization. The two smallest infants <2000 g underwent femoral arterial access with retrograde PDA closure under echocardiography guidance as described by Bentham et al. 22 The smallest 1700 g infant had unsuccessful percutaneous access requiring femoral arterial cutdown and subsequently developed transiently diminished pulses. Notably, the remaining 15 cases, including 7 infants with weight range 2-5.65 kg, underwent the procedure in a catheterization suite using both femoral venous and arterial access. Device delivery was successful with complete shunt occlusion in 13 cases at the end of the procedure. antegrade diastolic flow was seen in either the LPA or aorta, the device was recollected and repositioned or removed. Using this approach, implantation success rate was 88% (21/24) in this group of ELBW infants with a median weight of 1249 g (755-2380 g).
Complete occlusion was achieved in all patients by the end of the procedure. Devices were removed in the three unsuccessful cases due to concern for LPA stenosis and these infants underwent uncomplicated surgical ligation. Procedural complications were recognized in 3 patients, 2 of whom were remedied with catheter techniques in the same procedure (both with significant descending aortic obstruction which was noted immediately after device release and was corrected with device repositioning). One patient with a large 6 mm device developed LPA stenosis secondary to device encroachment and compression of the LPA. This infant underwent LPA stent placement several weeks after the procedure with a good result. When compared to a historical surgical ligation control group, it appeared that this group of ELBW infants had a significantly lower incidence of cardiorespiratory compromise (so-called postligation syndrome). 28 There was one late death A meta-analysis of percutaneous PDA closure in infants was performed in 2017 comparing 38 studies and 635 procedures. 17 Of these, 19% of patients weighed <3 kg (n = 103) and 48% (n = 255) weighed 3-6 kg at the time of the procedure. devices are particularly suited for PDA closure in small and preterm infants. 
| FUTURE DIREC TIONS: IMPLIC ATIONS FOR RE S E ARCH AND MANAG EMENT G UIDELINE

| CON CLUS I ON AND RECOMMENDATIONS
Transcatheter PDA closure in preterm ELBW infants is now technically feasible with high ductal occlusion rates and acceptable com- 
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